Market Place
Sourcing Support
Monopar Therapeutics Proposes Another Common Stock Offering
28 Oct 2024 //
#N/A
Monopar Therapeutics Announces $19.2M Public Offering
28 Oct 2024 //
#N/A
AZ licenses discarded rare disease drug to Monopar Therapeutics
25 Oct 2024 //
FIERCE BIOTECH
Monopar Presents Clinical Dosimetry Data At EANM 2024
22 Oct 2024 //
GLOBENEWSWIRE
Monopar Expands Radiopharma IP Portfolio With Patent Filing
15 Oct 2024 //
GLOBENEWSWIRE
Monopar Initiates Trial Of uPAR-Targeted Therapy In Cancers
07 Oct 2024 //
GLOBENEWSWIRE
Monopar Announces Positive Data On MNPR-101-Zr Tumor Targeting
12 Sep 2024 //
GLOBENEWSWIRE
Monopar To Join H.C. Wainwright Investment Conference
04 Sep 2024 //
GLOBENEWSWIRE
Monopar Regains Compliance with Nasdaq Minimum Bid Price Rule
27 Aug 2024 //
GLOBENEWSWIRE
Monopar Cleared For Phase 1 Trial Of Radiopharmaceutical In Cancer
21 Aug 2024 //
GLOBENEWSWIRE
Monopar Announces Initial Data From Phase 1 Trial Of MNPR-101-Zr Radiopharma
14 Aug 2024 //
GLOBENEWSWIRE
Monopar Reports Q2 2024 Results And Recent Developments
09 Aug 2024 //
GLOBENEWSWIRE
Monopar Therapeutics Announces 1-for-5 Reverse Stock Split
09 Aug 2024 //
GLOBENEWSWIRE
Monopar Enrolls First Patient In Radiopharmaceutical Phase 1 Trial
09 Jul 2024 //
GLOBENEWSWIRE
Monopar MNPR-101-RIT Abstract Accepted as Top Oral Presentation at EANM’24
25 Jun 2024 //
GLOBENEWSWIRE
Monopar and NorthStar Amend & Extend Collaboration
11 Jun 2024 //
GLOBENEWSWIRE
Monopar Presents uPAR As Cancer Target, Clinical Program At SNMMI 2024
10 Jun 2024 //
GLOBENEWSWIRE
Monopar Announces CFO Succession
24 May 2024 //
GLOBENEWSWIRE
Monopar Focuses On Radiopharma Pipeline In Q1 2024
09 May 2024 //
GLOBENEWSWIRE
Rallybio reigns in preclinical, Monopar pivots to radiopharma
09 May 2024 //
FIERCE BIOTECH
Monopar`s Radiopharma Abstract At SNMMI 2024 Annual Meeting
18 Apr 2024 //
GLOBENEWSWIRE
Monopar Files Patent Protecting MNPR-101 Radiopharma Optimization Findings
16 Apr 2024 //
GLOBENEWSWIRE
Monopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr
10 Apr 2024 //
GLOBENEWSWIRE
Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results
28 Mar 2024 //
GLOBENEWSWIRE
Monopar Announces Positive Data for its MNPR-101 Program
05 Mar 2024 //
GLOBENEWSWIRE
Monopar Provides Update on MNPR-101-Zr Radiopharma Clinical Trial
27 Feb 2024 //
GLOBENEWSWIRE
Monopar Announces Promising Preclinical Data for its MNPR-101
22 Feb 2024 //
GLOBENEWSWIRE
Monopar Receives Clearance to Proceed with Phase 1 Trial of MNPR-101-Zr
20 Feb 2024 //
GLOBENEWSWIRE
Monopar Therapeutics Reports Third Quarter 2023 Financial Results
09 Nov 2023 //
GLOBENEWSWIRE
Monopar Presents Data Showing Tumor Reduction Benefit of Camsirubicin from Ph 1b
01 Nov 2023 //
GLOBENEWSWIRE
Monopar to Participate in the Roth MKM 2023 Healthcare Opportunities Conference
10 Oct 2023 //
GLOBENEWSWIRE
Monopar to Participate in the H.C. Wainwright 25th Annual Global Conference
05 Sep 2023 //
GLOBENEWSWIRE
Monopar Therapeutics Reports Second Quarter 2023 Financial Results
10 Aug 2023 //
GLOBENEWSWIRE
Monopar Provides Encouraging Camsirubicin Clinical Data Update
08 Aug 2023 //
GLOBENEWSWIRE
Monopar Announces MNPR-101 Collaboration with National University of Singapore
11 Jul 2023 //
GLOBENEWSWIRE
Monopar to Participate in the Radiopharma Forum by the Lake 2023
21 Jun 2023 //
GLOBENEWSWIRE
Monopar to Participate in the Maxim Group™s Healthcare Virtual Conference
14 Jun 2023 //
GLOBENEWSWIRE
Monopar Announces Encouraging Camsirubicin Phase 1b Trial Update
01 Jun 2023 //
GLOBENEWSWIRE
Monopar Therapeutics Reports First Quarter 2023 Financial Results
11 May 2023 //
GLOBENEWSWIRE
Monopar to Present at the Jefferies Radiopharma Innovation Summit
28 Mar 2023 //
GLOBENEWSWIRE
Monopar spikes chemo side effect drug after phase 2/3 analysis
28 Mar 2023 //
FIERCE BIOTECH
Monopar Announces Result Phase 2b/3 VOICE Trial Evaluating Validive
27 Mar 2023 //
GLOBENEWSWIRE
Monopar Therapeutics Reports Fourth Quarter & Full-Year 2022 Financial Results
23 Mar 2023 //
GLOBENEWSWIRE
Monopar to Present at the 35th Annual Roth Conference
07 Mar 2023 //
GLOBENEWSWIRE
Monopar and NorthStar Announce Expanded Radiopharma Program
27 Feb 2023 //
GLOBENEWSWIRE
Monopar Announces Camsirubicin Clinical Program Update
14 Feb 2023 //
GLOBENEWSWIRE
Monopar Announces Timeline of Upcoming Q1 2023 Data Events
26 Jan 2023 //
GLOBENEWSWIRE
Monopar Announces Successful Advancement of Camsirubicin Ph1b Clinical Trial
18 Jan 2023 //
GLOBENEWSWIRE
Monopar Announces Promising MNPR-202 Data from Ongoing National University
12 Dec 2022 //
GLOBENEWSWIRE
Monopar Announces Encouraging Clinical Data from Ongoing Camsirubicin Ph1b Trial
16 Nov 2022 //
GLOBENEWSWIRE
Monopar Therapeutics Reports 3Q 2022 Financial Results and Recent Developments
10 Nov 2022 //
GLOBENEWSWIRE
Monopar Announces Timeline of Data Events for Validive, Camsirubicin, & MNPR-202
27 Oct 2022 //
GLOBENEWSWIRE
Monopar Announces Presentation Selected for 2022 ASH 64th Annual Meeting
19 Oct 2022 //
GLOBENEWSWIRE
Monopar Announces Completion of Ph 2b & Ph3 Enrollment
05 Oct 2022 //
GLOBENEWSWIRE
Monopar to Present at Roth Inaugural Healthcare Opportunities Conference
28 Sep 2022 //
GLOBENEWSWIRE
Monopar Therapeutics Reports Q2 2022 Rusult and Recent Program Developments
11 Aug 2022 //
GLOBENEWSWIRE
Monopar Therapeutics Reports First Quarter 2022 Financial Results
12 May 2022 //
GLOBENEWSWIRE
Monopar Tx Reports Q4 and Full-Year 2021 Financial Results
24 Mar 2022 //
GLOBENEWSWIRE
Monopar Announces Clinical and Preclinical Program Updates
15 Feb 2022 //
GLOBENEWSWIRE
Monopar Reports Q3 2021 Financial Results and Recent Clinical Developments
12 Nov 2021 //
GLOBENEWSWIRE
